Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 504-505, 2005; 10.1373/clinchem.2004.044990
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rifai, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rifai, N.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:504-505.)
© 2005 American Association for Clinical Chemistry, Inc.

Opinion

High-Sensitivity C-Reactive Protein: A Useful Marker for Cardiovascular Disease Risk Prediction and the Metabolic Syndrome

Nader Rifai

Children’s Hospital, and, Harvard Medical School, Boston, MA

Address for correspondence: Children’s Hospital, Department of Laboratory Medicine, 300 Longwood Ave., Boston, MA 02115. Fax 617-730-0383; Nader.rifai@tch.harvard.edu.

The first 20% of the full text of this article appears below.

Every year, 1.3 million Americans suffer a myocardial infarction with only one half of them exhibiting evidence of dyslipidemia. The identification of additional risk factors for cardiovascular disease is therefore of paramount importance. Of the examined novel biochemical markers, high-sensitivity C-reactive protein (hs-CRP) is the most promising. To date, 22 prospective epidemiologic studies have demonstrated that hs-CRP is a strong predictor of future vascular disease, 6 cohort studies have shown that hs-CRP measurements add prognostic value beyond that available from the Framingham risk score, and 8 cohort studies have confirmed that hs-CRP adds prognostic information in the metabolic syndrome and in the prediction of type 2 diabetes (1). These studies, done by various groups in Europe and the United States, examined middle-aged and elderly men and women, and some included different ethnic and racial groups. As a result of these findings and the fact that hs-CRP can be reliably and accurately measured by clinical laboratories, the American Heart Association (AHA) and the CDC issued joint guidelines about the implementation of hs-CRP measurement as part of the global risk assessment of cardiovascular disease (2).

In this Journal, Levinson et al. (3) recently questioned . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.